

Global Oligonucleotide Therapy-based Drug Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GFED77D80697EN.html>

Date: November 2023

Pages: 159

Price: US\$ 4,480.00 (Single User License)

ID: GFED77D80697EN

Abstracts

The global Oligonucleotide Therapy-based Drug market size is expected to reach \$ 84010 million by 2029, rising at a market growth of 3.6% CAGR during the forecast period (2023-2029).

The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.

Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation,

non-coding RNA inhibition, gene activation and programmed gene editing.

This report studies the global Oligonucleotide Therapy-based Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Oligonucleotide Therapy-based Drug, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oligonucleotide Therapy-based Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Oligonucleotide Therapy-based Drug total market, 2018-2029, (USD Million)

Global Oligonucleotide Therapy-based Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Oligonucleotide Therapy-based Drug total market, key domestic companies and share, (USD Million)

Global Oligonucleotide Therapy-based Drug revenue by player and market share 2018-2023, (USD Million)

Global Oligonucleotide Therapy-based Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global Oligonucleotide Therapy-based Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Oligonucleotide Therapy-based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oligonucleotide Therapy-based Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Oligonucleotide Therapy-based Drug Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Oligonucleotide Therapy-based Drug Market, Segmentation by Type

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Global Oligonucleotide Therapy-based Drug Market, Segmentation by Application

Neuromuscular Diseases

hATTR

COVID-19

Other

Companies Profiled:

Sarepta Therapeutics

Ionis Pharmaceuticals

Anylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Key Questions Answered

1. How big is the global Oligonucleotide Therapy-based Drug market?
2. What is the demand of the global Oligonucleotide Therapy-based Drug market?
3. What is the year over year growth of the global Oligonucleotide Therapy-based Drug market?
4. What is the total value of the global Oligonucleotide Therapy-based Drug market?
5. Who are the major players in the global Oligonucleotide Therapy-based Drug market?

Contents

1 SUPPLY SUMMARY

- 1.1 Oligonucleotide Therapy-based Drug Introduction
- 1.2 World Oligonucleotide Therapy-based Drug Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Oligonucleotide Therapy-based Drug Total Market by Region (by Headquarter Location)
 - 1.3.1 World Oligonucleotide Therapy-based Drug Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Oligonucleotide Therapy-based Drug Market Size (2018-2029)
 - 1.3.3 China Oligonucleotide Therapy-based Drug Market Size (2018-2029)
 - 1.3.4 Europe Oligonucleotide Therapy-based Drug Market Size (2018-2029)
 - 1.3.5 Japan Oligonucleotide Therapy-based Drug Market Size (2018-2029)
 - 1.3.6 South Korea Oligonucleotide Therapy-based Drug Market Size (2018-2029)
 - 1.3.7 ASEAN Oligonucleotide Therapy-based Drug Market Size (2018-2029)
 - 1.3.8 India Oligonucleotide Therapy-based Drug Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Oligonucleotide Therapy-based Drug Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Oligonucleotide Therapy-based Drug Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.2 World Oligonucleotide Therapy-based Drug Consumption Value by Region
 - 2.2.1 World Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023)
 - 2.2.2 World Oligonucleotide Therapy-based Drug Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.4 China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.5 Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.6 Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.7 South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.8 ASEAN Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
- 2.9 India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)

3 WORLD OLIGONUCLEOTIDE THERAPY-BASED DRUG COMPANIES COMPETITIVE ANALYSIS

3.1 World Oligonucleotide Therapy-based Drug Revenue by Player (2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Oligonucleotide Therapy-based Drug Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Oligonucleotide Therapy-based Drug in 2022

3.2.3 Global Concentration Ratios (CR8) for Oligonucleotide Therapy-based Drug in 2022

3.3 Oligonucleotide Therapy-based Drug Company Evaluation Quadrant

3.4 Oligonucleotide Therapy-based Drug Market: Overall Company Footprint Analysis

3.4.1 Oligonucleotide Therapy-based Drug Market: Region Footprint

3.4.2 Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint

3.4.3 Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Oligonucleotide Therapy-based Drug Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Oligonucleotide Therapy-based Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)

4.1.2 United States VS China: Oligonucleotide Therapy-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)

4.2 United States Based Companies VS China Based Companies: Oligonucleotide Therapy-based Drug Consumption Value Comparison

4.2.1 United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)

4.3 United States Based Oligonucleotide Therapy-based Drug Companies and Market

Share, 2018-2023

4.3.1 United States Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)

4.4 China Based Companies Oligonucleotide Therapy-based Drug Revenue and Market Share, 2018-2023

4.4.1 China Based Oligonucleotide Therapy-based Drug Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)

4.5 Rest of World Based Oligonucleotide Therapy-based Drug Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Oligonucleotide Therapy-based Drug Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Antisense Oligonucleotides (ASO)

5.2.2 siRNA

5.2.3 mRNA

5.3 Market Segment by Type

5.3.1 World Oligonucleotide Therapy-based Drug Market Size by Type (2018-2023)

5.3.2 World Oligonucleotide Therapy-based Drug Market Size by Type (2024-2029)

5.3.3 World Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Oligonucleotide Therapy-based Drug Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Neuromuscular Diseases

6.2.2 hATTR

6.2.3 COVID-19

6.2.4 Other

6.2.5 Other

6.3 Market Segment by Application

6.3.1 World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2023)

6.3.2 World Oligonucleotide Therapy-based Drug Market Size by Application (2024-2029)

6.3.3 World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Sarepta Therapeutics

7.1.1 Sarepta Therapeutics Details

7.1.2 Sarepta Therapeutics Major Business

7.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Services

7.1.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Sarepta Therapeutics Recent Developments/Updates

7.1.6 Sarepta Therapeutics Competitive Strengths & Weaknesses

7.2 Ionis Pharmaceuticals

7.2.1 Ionis Pharmaceuticals Details

7.2.2 Ionis Pharmaceuticals Major Business

7.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services

7.2.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Ionis Pharmaceuticals Recent Developments/Updates

7.2.6 Ionis Pharmaceuticals Competitive Strengths & Weaknesses

7.3 Alnylam

7.3.1 Alnylam Details

7.3.2 Alnylam Major Business

7.3.3 Alnylam Oligonucleotide Therapy-based Drug Product and Services

7.3.4 Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Alnylam Recent Developments/Updates

7.3.6 Alnylam Competitive Strengths & Weaknesses

7.4 Biogen

7.4.1 Biogen Details

7.4.2 Biogen Major Business

7.4.3 Biogen Oligonucleotide Therapy-based Drug Product and Services

7.4.4 Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Biogen Recent Developments/Updates

7.4.6 Biogen Competitive Strengths & Weaknesses

7.5 Nippon Shinyaku

7.5.1 Nippon Shinyaku Details

7.5.2 Nippon Shinyaku Major Business

7.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Services

7.5.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Nippon Shinyaku Recent Developments/Updates

7.5.6 Nippon Shinyaku Competitive Strengths & Weaknesses

7.6 Sobi

7.6.1 Sobi Details

7.6.2 Sobi Major Business

7.6.3 Sobi Oligonucleotide Therapy-based Drug Product and Services

7.6.4 Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Sobi Recent Developments/Updates

7.6.6 Sobi Competitive Strengths & Weaknesses

7.7 Novartis

7.7.1 Novartis Details

7.7.2 Novartis Major Business

7.7.3 Novartis Oligonucleotide Therapy-based Drug Product and Services

7.7.4 Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 Novartis Recent Developments/Updates

7.7.6 Novartis Competitive Strengths & Weaknesses

7.8 BioNTech

7.8.1 BioNTech Details

7.8.2 BioNTech Major Business

7.8.3 BioNTech Oligonucleotide Therapy-based Drug Product and Services

7.8.4 BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 BioNTech Recent Developments/Updates

- 7.8.6 BioNTech Competitive Strengths & Weaknesses
- 7.9 Pfizer
 - 7.9.1 Pfizer Details
 - 7.9.2 Pfizer Major Business
 - 7.9.3 Pfizer Oligonucleotide Therapy-based Drug Product and Services
 - 7.9.4 Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.9.5 Pfizer Recent Developments/Updates
 - 7.9.6 Pfizer Competitive Strengths & Weaknesses
- 7.10 Moderna Therapeutics
 - 7.10.1 Moderna Therapeutics Details
 - 7.10.2 Moderna Therapeutics Major Business
 - 7.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Services
 - 7.10.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.10.5 Moderna Therapeutics Recent Developments/Updates
 - 7.10.6 Moderna Therapeutics Competitive Strengths & Weaknesses
- 7.11 Jazz Pharmaceuticals
 - 7.11.1 Jazz Pharmaceuticals Details
 - 7.11.2 Jazz Pharmaceuticals Major Business
 - 7.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
 - 7.11.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.11.5 Jazz Pharmaceuticals Recent Developments/Updates
 - 7.11.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
- 7.12 CureVac
 - 7.12.1 CureVac Details
 - 7.12.2 CureVac Major Business
 - 7.12.3 CureVac Oligonucleotide Therapy-based Drug Product and Services
 - 7.12.4 CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.12.5 CureVac Recent Developments/Updates
 - 7.12.6 CureVac Competitive Strengths & Weaknesses
- 7.13 Regulus Therapeutics
 - 7.13.1 Regulus Therapeutics Details
 - 7.13.2 Regulus Therapeutics Major Business
 - 7.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and

Services

7.13.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.13.5 Regulus Therapeutics Recent Developments/Updates

7.13.6 Regulus Therapeutics Competitive Strengths & Weaknesses

7.14 ProQR

7.14.1 ProQR Details

7.14.2 ProQR Major Business

7.14.3 ProQR Oligonucleotide Therapy-based Drug Product and Services

7.14.4 ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.14.5 ProQR Recent Developments/Updates

7.14.6 ProQR Competitive Strengths & Weaknesses

7.15 Secarna

7.15.1 Secarna Details

7.15.2 Secarna Major Business

7.15.3 Secarna Oligonucleotide Therapy-based Drug Product and Services

7.15.4 Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.15.5 Secarna Recent Developments/Updates

7.15.6 Secarna Competitive Strengths & Weaknesses

7.16 MiNA Therapeutics

7.16.1 MiNA Therapeutics Details

7.16.2 MiNA Therapeutics Major Business

7.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Services

7.16.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.16.5 MiNA Therapeutics Recent Developments/Updates

7.16.6 MiNA Therapeutics Competitive Strengths & Weaknesses

7.17 Sylentis

7.17.1 Sylentis Details

7.17.2 Sylentis Major Business

7.17.3 Sylentis Oligonucleotide Therapy-based Drug Product and Services

7.17.4 Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)

7.17.5 Sylentis Recent Developments/Updates

7.17.6 Sylentis Competitive Strengths & Weaknesses

7.18 Arrowhead

7.18.1 Arrowhead Details

- 7.18.2 Arrowhead Major Business
- 7.18.3 Arrowhead Oligonucleotide Therapy-based Drug Product and Services
- 7.18.4 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
- 7.18.5 Arrowhead Recent Developments/Updates
- 7.18.6 Arrowhead Competitive Strengths & Weaknesses
- 7.19 Silence Therapeutics
 - 7.19.1 Silence Therapeutics Details
 - 7.19.2 Silence Therapeutics Major Business
 - 7.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Services
 - 7.19.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.19.5 Silence Therapeutics Recent Developments/Updates
 - 7.19.6 Silence Therapeutics Competitive Strengths & Weaknesses
- 7.20 Dicerna
 - 7.20.1 Dicerna Details
 - 7.20.2 Dicerna Major Business
 - 7.20.3 Dicerna Oligonucleotide Therapy-based Drug Product and Services
 - 7.20.4 Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.20.5 Dicerna Recent Developments/Updates
 - 7.20.6 Dicerna Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Oligonucleotide Therapy-based Drug Industry Chain
- 8.2 Oligonucleotide Therapy-based Drug Upstream Analysis
- 8.3 Oligonucleotide Therapy-based Drug Midstream Analysis
- 8.4 Oligonucleotide Therapy-based Drug Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Oligonucleotide Therapy-based Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Oligonucleotide Therapy-based Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Oligonucleotide Therapy-based Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Oligonucleotide Therapy-based Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Oligonucleotide Therapy-based Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Oligonucleotide Therapy-based Drug Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Oligonucleotide Therapy-based Drug Players in 2022

Table 12. World Oligonucleotide Therapy-based Drug Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Oligonucleotide Therapy-based Drug Company Evaluation Quadrant

Table 14. Head Office of Key Oligonucleotide Therapy-based Drug Player

Table 15. Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint

Table 16. Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint

Table 17. Oligonucleotide Therapy-based Drug Mergers & Acquisitions Activity

Table 18. United States VS China Oligonucleotide Therapy-based Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Oligonucleotide Therapy-based Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Oligonucleotide Therapy-based Drug Companies,

Headquarters (States, Country)

Table 21. United States Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)

Table 23. China Based Oligonucleotide Therapy-based Drug Companies, Headquarters (Province, Country)

Table 24. China Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)

Table 26. Rest of World Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)

Table 29. World Oligonucleotide Therapy-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Oligonucleotide Therapy-based Drug Market Size by Type (2018-2023) & (USD Million)

Table 31. World Oligonucleotide Therapy-based Drug Market Size by Type (2024-2029) & (USD Million)

Table 32. World Oligonucleotide Therapy-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2023) & (USD Million)

Table 34. World Oligonucleotide Therapy-based Drug Market Size by Application (2024-2029) & (USD Million)

Table 35. Sarepta Therapeutics Basic Information, Area Served and Competitors

Table 36. Sarepta Therapeutics Major Business

Table 37. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Services

Table 38. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Sarepta Therapeutics Recent Developments/Updates

Table 40. Sarepta Therapeutics Competitive Strengths & Weaknesses

Table 41. Ionis Pharmaceuticals Basic Information, Area Served and Competitors

Table 42. Ionis Pharmaceuticals Major Business

Table 43. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services

Table 44. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Ionis Pharmaceuticals Recent Developments/Updates

Table 46. Ionis Pharmaceuticals Competitive Strengths & Weaknesses

Table 47. Alnylam Basic Information, Area Served and Competitors

Table 48. Alnylam Major Business

Table 49. Alnylam Oligonucleotide Therapy-based Drug Product and Services

Table 50. Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Alnylam Recent Developments/Updates

Table 52. Alnylam Competitive Strengths & Weaknesses

Table 53. Biogen Basic Information, Area Served and Competitors

Table 54. Biogen Major Business

Table 55. Biogen Oligonucleotide Therapy-based Drug Product and Services

Table 56. Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Biogen Recent Developments/Updates

Table 58. Biogen Competitive Strengths & Weaknesses

Table 59. Nippon Shinyaku Basic Information, Area Served and Competitors

Table 60. Nippon Shinyaku Major Business

Table 61. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Services

Table 62. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Nippon Shinyaku Recent Developments/Updates

Table 64. Nippon Shinyaku Competitive Strengths & Weaknesses

Table 65. Sobi Basic Information, Area Served and Competitors

Table 66. Sobi Major Business

Table 67. Sobi Oligonucleotide Therapy-based Drug Product and Services

Table 68. Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Sobi Recent Developments/Updates

Table 70. Sobi Competitive Strengths & Weaknesses

Table 71. Novartis Basic Information, Area Served and Competitors

Table 72. Novartis Major Business

Table 73. Novartis Oligonucleotide Therapy-based Drug Product and Services

Table 74. Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

- Table 75. Novartis Recent Developments/Updates
- Table 76. Novartis Competitive Strengths & Weaknesses
- Table 77. BioNTech Basic Information, Area Served and Competitors
- Table 78. BioNTech Major Business
- Table 79. BioNTech Oligonucleotide Therapy-based Drug Product and Services
- Table 80. BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. BioNTech Recent Developments/Updates
- Table 82. BioNTech Competitive Strengths & Weaknesses
- Table 83. Pfizer Basic Information, Area Served and Competitors
- Table 84. Pfizer Major Business
- Table 85. Pfizer Oligonucleotide Therapy-based Drug Product and Services
- Table 86. Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Pfizer Recent Developments/Updates
- Table 88. Pfizer Competitive Strengths & Weaknesses
- Table 89. Moderna Therapeutics Basic Information, Area Served and Competitors
- Table 90. Moderna Therapeutics Major Business
- Table 91. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Services
- Table 92. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 93. Moderna Therapeutics Recent Developments/Updates
- Table 94. Moderna Therapeutics Competitive Strengths & Weaknesses
- Table 95. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
- Table 96. Jazz Pharmaceuticals Major Business
- Table 97. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
- Table 98. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 99. Jazz Pharmaceuticals Recent Developments/Updates
- Table 100. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
- Table 101. CureVac Basic Information, Area Served and Competitors
- Table 102. CureVac Major Business
- Table 103. CureVac Oligonucleotide Therapy-based Drug Product and Services
- Table 104. CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 105. CureVac Recent Developments/Updates
- Table 106. CureVac Competitive Strengths & Weaknesses

Table 107. Regulus Therapeutics Basic Information, Area Served and Competitors

Table 108. Regulus Therapeutics Major Business

Table 109. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Services

Table 110. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 111. Regulus Therapeutics Recent Developments/Updates

Table 112. Regulus Therapeutics Competitive Strengths & Weaknesses

Table 113. ProQR Basic Information, Area Served and Competitors

Table 114. ProQR Major Business

Table 115. ProQR Oligonucleotide Therapy-based Drug Product and Services

Table 116. ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 117. ProQR Recent Developments/Updates

Table 118. ProQR Competitive Strengths & Weaknesses

Table 119. Secarna Basic Information, Area Served and Competitors

Table 120. Secarna Major Business

Table 121. Secarna Oligonucleotide Therapy-based Drug Product and Services

Table 122. Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 123. Secarna Recent Developments/Updates

Table 124. Secarna Competitive Strengths & Weaknesses

Table 125. MiNA Therapeutics Basic Information, Area Served and Competitors

Table 126. MiNA Therapeutics Major Business

Table 127. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Services

Table 128. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 129. MiNA Therapeutics Recent Developments/Updates

Table 130. MiNA Therapeutics Competitive Strengths & Weaknesses

Table 131. Sylentis Basic Information, Area Served and Competitors

Table 132. Sylentis Major Business

Table 133. Sylentis Oligonucleotide Therapy-based Drug Product and Services

Table 134. Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 135. Sylentis Recent Developments/Updates

Table 136. Sylentis Competitive Strengths & Weaknesses

Table 137. Arrowhead Basic Information, Area Served and Competitors

Table 138. Arrowhead Major Business

Table 139. Arrowhead Oligonucleotide Therapy-based Drug Product and Services

Table 140. Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 141. Arrowhead Recent Developments/Updates

Table 142. Arrowhead Competitive Strengths & Weaknesses

Table 143. Silence Therapeutics Basic Information, Area Served and Competitors

Table 144. Silence Therapeutics Major Business

Table 145. Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Services

Table 146. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 147. Silence Therapeutics Recent Developments/Updates

Table 148. Dicerna Basic Information, Area Served and Competitors

Table 149. Dicerna Major Business

Table 150. Dicerna Oligonucleotide Therapy-based Drug Product and Services

Table 151. Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 152. Global Key Players of Oligonucleotide Therapy-based Drug Upstream (Raw Materials)

Table 153. Oligonucleotide Therapy-based Drug Typical Customers

LIST OF FIGURE

Figure 1. Oligonucleotide Therapy-based Drug Picture

Figure 2. World Oligonucleotide Therapy-based Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Oligonucleotide Therapy-based Drug Total Market Size (2018-2029) & (USD Million)

Figure 4. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Oligonucleotide Therapy-based Drug Revenue

(2018-2029) & (USD Million)

Figure 10. South Korea Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)

Figure 13. Oligonucleotide Therapy-based Drug Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 16. World Oligonucleotide Therapy-based Drug Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 18. China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 23. India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Oligonucleotide Therapy-based Drug by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Oligonucleotide Therapy-based Drug Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Oligonucleotide Therapy-based Drug Markets in 2022

Figure 27. United States VS China: Oligonucleotide Therapy-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Oligonucleotide Therapy-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Oligonucleotide Therapy-based Drug Market Size Market Share by Type in 2022

Figure 31. Antisense Oligonucleotides (ASO)

Figure 32. siRNA

Figure 33. mRNA

Figure 34. World Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2018-2029)

Figure 35. World Oligonucleotide Therapy-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 36. World Oligonucleotide Therapy-based Drug Market Size Market Share by Application in 2022

Figure 37. Neuromuscular Diseases

Figure 38. hATTR

Figure 39. COVID-19

Figure 40. Other

Figure 41. Oligonucleotide Therapy-based Drug Industrial Chain

Figure 42. Methodology

Figure 43. Research Process and Data Source

I would like to order

Product name: Global Oligonucleotide Therapy-based Drug Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GFED77D80697EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFED77D80697EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

